A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 261-268

  Figlin, Robert A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

AGS 003; autologous dendritic cell vaccine; immunotherapy; renal cell carcinoma; sunitinib; targeted therapy; VEGF

Indexed keywords

AGS 003; ALPHA INTERFERON; AUTOIMMUNE VACCINE; CANCER VACCINE; DENDRITIC CELL VACCINE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PEPTIDE VACCINE; PERSONALIZED VACCINE; SUNITINIB; UNCLASSIFIED DRUG; VACCINE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; EVEROLIMUS; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; RNA; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TIVOZANIB; TUMOR ANTIGEN; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ACTIVE IMMUNIZATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DENDRITIC CELL; DRUG EFFECTS; ELECTROPORATION; IMMUNOLOGY; KIDNEY NEOPLASMS; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DENDRITIC CELLS; ELECTROPORATION; HUMANS; IMMUNOTHERAPY, ACTIVE; INDIVIDUALIZED MEDICINE; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; QUINOLINES; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84899571127     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.168     Document Type: Article

References (74)

1. Cancer Facts & Figures 2013. American Cancer Society, GA, USA (2013).
2. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: Molecular mechanisms and newer therapeutic options. Curr. Opin. Nephrol. Hypertens. 11(1), 37-42 (2002).
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. v1.2013. National Comprehensive Cancer Network, PA, USA, 1-24 (2013).
4. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-Activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889-897 (1987).
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
6. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity. Cancer Res. 48(1), 206-214 (1988).
7. Thurnher M, Radmayr C, Ramoner R et al. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer 68(1), 1-7 (1996).
8. George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. J. Natl Compr. Canc. Netw. 9(9), 1011-1018 (2011).
9. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
10. Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma: Identification of features favoring upfront IL-2-based immunotherapy. Med. Oncol. 26(Suppl. 1), 18-22 (2009).
11. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
12. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
13. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 115(10 Suppl.), 2298-2305 (2009).
14. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist 16(Suppl. 2), 14-22 (2011).
15. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol. 7(6), 327-338 (2010).
16. Rini BI. Vascular endothelial growth factor-Targeted therapy in metastatic renal cell carcinoma. Cancer 115(10 Suppl.), 2306-2312 (2009).
17. Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib development in solid malignancies: Focus on metastatic renal cell carcinoma. Clin. Adv. Hematol. Oncol. 10(5), 307-314 (2012).
18. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R. D. 11(2), 113-126 (2011).
19. Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116(23), 5383-5390 (2010).
20. Hutson TE, Gallardo J, Lesovoy V et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 31(Suppl. 6), LBA348 (2013).
21. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009).
22. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
23. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369(8), 722-731 (2013).
24. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
25. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
26. Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 7, 139-148 (2013).
27. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a Phase III trial. J. Clin. Oncol. doi:10.1200/JCO.2012.47.4940 (2013) (Epub ahead of print).
28. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25(4), 835-852 (2011).
29. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-Tumor immunity. Curr. Opin. Immunol. 24(2), 207-212 (2012).
30. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
31. McDermott DF, Drake CG, Sznol M et al. A Phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. J. Clin. Oncol. 29(Suppl. 7), Abstract 331 (2011).
32. Eggermont AM. Can immuno-oncology offer a truly pan-Tumour approach to therapy? Ann. Oncol. 23(Suppl. 8), viii53-viii57 (2012).
33. Cohen S, Kaufman HL. TG-4010 transgene. Curr. Opin. Investig. Drugs 5(12), 1319-1328 (2004).
34. Aubert S, Fauquette V, Hemon B et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 69(14), 5707-5715 (2009).
35. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5(8), 690-699 (2003).
36. Oudard S, Rixe O, Beuselinck B et al. A Phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: Clinical and immunological findings. Cancer Immunol. Immunother. 60(2), 261-271 (2011).
37. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61(1), 89-95 (1990).
38. Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled Phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010).
39. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G. Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 9(8), 1043-1055 (2009).
40. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254-1261 (2012).
41. Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2(1), e22246 (2013).
42. Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: Vaccines and combination immunotherapies. Expert Rev. Vaccines 12(3), 285-295 (2013).
43. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
44. Banchereau J, Paczesny S, Blanco P et al. Dendritic cells: Controllers of the immune system and a new promise for immunotherapy. Ann. NY Acad. Sci. 987, 180-187 (2003).
45. Tacken PJ, De Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
46. Yanofsky VR, Mitsui H, Felsen D, Carucci JA. Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy. Clin. Dev. Immunol. 2013, 624123 (2013).
47. Draube A, Klein-Gonzalez N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: A systematic review and meta-Analysis. PLoS ONE 6(4), e18801 (2011).
48. Figlin RA, Amin A, Dudek A et al. Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 30(Suppl. 5), Abstract 348 (2012).
49. Amin A, Dudek A, Logan T et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 31(Suppl. 6), Abstract 357 (2013).
50. Slagter-Jager JG, Raney A, Lewis WE, Debenedette MA, Nicolette CA, Tcherepanova IY. Evaluation of RNA amplification methods to improve DC immunotherapy antigen presentation and immune response. Mol. Ther. Nucleic Acids 2, e91 (2013).
51. Tcherepanova I, Harris J, Starr A et al. Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection. PLoS ONE 3(1), e1489 (2008).
52. Calderhead DM, Debenedette MA, Ketteringham H et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J. Immunother. 31(8), 731-741 (2008).
53. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat. Immunol. 12(9), 908-913 (2011).
54. Porta C, Bonomi L, Lillaz B et al. Renal cell carcinoma-induced immunosuppression: An immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 27(1A), 165-173 (2007).
55. Coates PT, Colvin BL, Hackstein H, Thomson AW. Manipulation of dendritic cells as an approach to improved outcomes in transplantation. Expert Rev. Mol. Med. 4(3), 1-21 (2002).
56. Debenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J. Immunother. 34(1), 45-57 (2011).
57. Pages F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27(35), 5944-5951 (2009).
58. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69(6), 2506-2513 (2009).
59. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 130(8), 1948-1959 (2012).
60. Bose A, Taylor JL, Alber S et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-Tumor immunity in concert with specific vaccination. Int. J. Cancer 129(9), 2158-2170 (2011).
61. Dall'Oglio MF, Sousa-Canavez JM, Tanno FY et al. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy. Int. Braz. J. Urol. 37(2), 180-185; discussion: 185-186 (2011).
62. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
63. Figlin RA, Nicolette CA, Amin A et al. Monitoring T-cell responses in a Phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J. Clin. Oncol. 29(Suppl.), Abstract 2532 (2011).
64. Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008).
65. Tran HT, Liu Y, Zurita AJ et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of Phase 2 and Phase 3 trials. Lancet Oncol. 13(8), 827-837 (2012).
66. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
67. Choueiri TK, Pal SK, McDermott DF et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30(Suppl.), Abstract 4504 (2012).
68. Angevin E, Grünwald V, Ravaud A et al. A Phase II study of dovitinib (TKI258), an FGFR-And VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J. Clin. Oncol. 29(Suppl.), Abstract 4551 (2011).
69. Vogelzang NJ, Signorovitch JE, Lin PL et al. Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States. J. Clin. Oncol. 31(Suppl. 6), Abstract 418 (2013).
70. Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK. Recent advances in the therapy of castration-resistant prostate cancer: The price of progress. Maturitas 70(2), 194-196 (2011).
71. A Phase 2 randomized, double-blind, crossover, controlled, multi-center subject preference study of tivozanib hydrochloride versus sunitinib in the treatment of subjects with metastatic renal cell carcinoma. http:// clinicaltrials.gov/show/NCT01673386
72. A Phase IIB/III randomized, double-blind, placebo controlled study comparing first line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). http:// clinicaltrials.gov/show/NCT01383148
73. A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma. http://clinicaltrials.gov/ show/NCT01265901
74. An international Phase 3 randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (ADAPT). http://clinicaltrials.gov/show/NCT01582672